A cumulative isotretinoin target is a planning tool, not a universal quota that replaces examination and judgment. NICE describes a conventional course target of 120-150 mg/kg, while allowing earlier completion when the response is adequate and no new lesions have appeared for four to eight weeks. That is a recommendation within a particular guideline, not a worldwide rule for every product or patient.
The number can help organize treatment, but it cannot answer whether acne is still active, whether adverse effects have become unacceptable or whether the exact prescription remains appropriate. Those questions belong in the stopping decision.
How is the cumulative total calculated?
The prescribed amounts actually taken are added across the course, then related to body weight. If the daily dose changes, each period needs its own calculation. Days without capsules should not be counted as if treatment continued normally.
| Illustrative treatment period | Calculation | Amount taken |
|---|---|---|
| 30 days at 20 mg daily | 30 multiplied by 20 mg | 600 mg |
| 60 days at 40 mg daily | 60 multiplied by 40 mg | 2,400 mg |
| Combined exposure in this illustration | 600 mg plus 2,400 mg | 3,000 mg |
| Total relative to 60 kg | 3,000 mg divided by 60 kg | 50 mg/kg |
This example explains arithmetic only. It does not prescribe a schedule or establish a stopping point. The clinician should use the relevant weight and actual treatment history, especially if the course includes changes or interruptions.
Keep a simple record of dose dates rather than trying to reconstruct them from memory at the final appointment. The number of capsules dispensed is not always the number swallowed.
Why consider total exposure at all?
Course exposure has been studied in relation to remission and recurrence. A planning range can discourage stopping merely because the skin looks better for a few days. However, research does not identify one amount that guarantees the same outcome for every patient.
Observational recurrence studies can support associations but cannot remove differences in acne severity, tolerability, treatment access or the reasons a dose was chosen. A cumulative number may be relevant without being the only relevant variable.
The useful question is how the target fits the clinical plan. If it is treated as the sole endpoint, a patient may keep taking capsules despite sustained clearance and a substantial burden, or stop despite continuing inflammatory lesions because the calculator says the course is finished.
Which findings should accompany the number?
| Finding at review | Why it matters |
|---|---|
| No new lesions over a sustained interval | Helps establish the stability of the response |
| Continuing tender or deep lesions | Suggests that active disease still needs assessment |
| New scars | Raises concern about the consequences of ongoing inflammation |
| Flat residual color or old scars | Does not automatically represent continuing acne activity |
| Significant adverse effects or abnormal results | Can change the balance of benefit and further exposure |
| Missed doses, supply changes or a different product | Helps interpret the actual course rather than an assumed one |
Do not decide that every remaining visible mark requires additional exposure. Likewise, do not dismiss genuinely new lesions just because the course total has reached a commonly quoted threshold.
Why may a clinician finish below a commonly quoted target?
Guideline-supported flexibility can reflect an adequate, sustained clinical response. Other individual circumstances can also require reassessment of treatment, especially when unwanted effects create concern. Finishing early because of a medical problem is not the same as electively stopping without telling the prescriber.
Ask which reason applies. A clear explanation might focus on stable clearance and follow-up, or it might explain why continuing would impose an unacceptable risk. Either way, the record should distinguish actual exposure from the reason treatment ended.
Why might a course continue after reaching a target?
If lesions are still appearing, the clinician may need to reconsider the diagnosis, adherence, administration or overall regimen. Reaching a number does not establish that all active disease has resolved. It also does not automatically justify further treatment.
An extension needs a rationale and a new review point. Do not add leftover capsules to "protect the result" or choose a larger total because someone online describes it as relapse-proof. More exposure means more treatment, and the expected additional benefit needs to justify that burden.
At the final review, ask how clinical response, course exposure and tolerability were weighed together. Confirm any maintenance treatment, post-treatment safety instructions and the signs that should prompt another acne assessment. A documented stopping plan is more useful than a certificate that one arithmetic target has been reached.